Reduced expression of MST1 in del(20q) leads to pathological activation of NF-κB signaling and downstream inflammatory pathways. This identifies a novel treatment pathway through the inhibition of upstream mediators IRAK1/4.
Reduced expression of MST1 in del(20q) leads to pathological activation of NF-κB signaling and downstream inflammatory pathways. This identifies a novel treatment pathway through the inhibition of upstream mediators IRAK1/4.